atopic dermatitis,chronic urticaria and pruritus
Conditions
Interventions
Bepotastine besilate(14days),Wash out(7days) and d-Chlorpheniramine Maleate or Ketotifen(14days)
d-Chlorpheniramine Maleate or Ketotifen(14days),Wash out(7days) and Bepotastine besilate(14days)
Sponsors
Tokyo Woman's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who were diagnosed with atopic dermatitis, chronic urticaria, and pruritus 2) Patients who were scored NRS 3<= for pruritus 3) Patients who gave their written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients who have the history of hypersensitivity to any of the study drug 2)Patients who had been taking an anti-histamine drug within 7 days before the registration 3)Patients who are pregnant,might be pregnant, lactating ,or wishing a pregnancy during the study period. 4)Patients who are complaining of sleepiness due to the influence of a regularly used drug that is not an antihistamine 5)Patients who are commonly complaining of intense sleepiness 6)Patients who are considered unsuitable for this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of sleepiness (JESS score) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) NRS scoring for pruritus. 2) NRS scoring for sleepiness. 3) QOL with relation to skin diseases (Skindex-16). 4) Evaluation of severity of atopic dermatitis and evaluation of severity of pruritus in other skin diseases. 5) Safety | — |
Countries
Japan
Outcome results
None listed